Drug Trial Radar · NCT07762287
Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 22, 2026
Primary completion
Jan 22, 2027
Study completion Jan 22, 2027
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Aug 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is being done to compare two forms of the medicine elinzanetant, which is used to help manage hot flush symptoms related to changes in female hormones. The researchers want to find out whether a new tablet form of elinzanetant is absorbed and processed by the body of healthy women in a similar way than an existing capsule form. About 100 healthy women aged 18 to 65 will take part in this study. Each participant will receive both forms of the medicine at different times during the study. They will take the medicine once daily for several days under controlled conditions at a study center, and blood samples will be collected to measure how the body absorbs and handles the drug. The study is designed so that each participant can be compared to herself, helping researchers clearly understand any differences between the two formulations.
Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women
Interventions
Elinzanetant (BAY 3427080) treatment ADrug
Elinzanetant treatment A is administered orally once daily.
Elinzanetant (BAY 3427080) treatment BDrug
Elinzanetant treatment B is administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-Time Curve Over 24 Hours After Multiple Dosing (AUC(0-24)md)Time frame: On Day 11 of each 12-day treatment period (study intervention administered on Days 1-10)
- Maximum Observed Plasma Concentration After Multiple Dosing (Cmax,md)Time frame: On Day 11 of each 12-day treatment period (study intervention administered on Days 1-10)
- Minimum Observed Plasma Concentration During Dosing Interval After Multiple Dosing (Cmin,md)Time frame: On Day 11 of each 12-day treatment period (study intervention administered on Days 1-10)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences
Mount Royal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.